Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease

European Journal of Cancer

Volumn 44, Issue 3, 2008, Pages 427-431

  Bergeron, Christophe ^a   Thiesse, Philippe ^a   Rey, Annie ^b   Orbach, Daniel ^c   Boutard, Patrick ^d   Thomas, Caroline ^e   Schmitt, Claudine ^f   Scopinaro, Marcelo J ^g   Bernard, Frederic ^h   Stevens, Michael ⁱ   Oberlin, Odile ^b  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Children; Doxorubicin; Rhabdomyosarcoma

Indexed keywords

DOXORUBICIN;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RISK; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART FUNCTION; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RISK ASSESSMENT; SEPSIS; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 38749137720     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.12.007     Document Type: Article

References (17)

1. Bonadonna G., Monfardini S., De Lena M., Fossati-Bellani F., and Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30 (1970) 2572-2582
2. O'Bryan R.M., Luce J.K., Talley R.W., Gottlieb J.A., Baker L.H., and Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 32 (1973) 1-8
3. Tan C., Etcubanas E., Wollner N., et al. Adriamycin - an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32 (1973) 9-17
4. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 (1993) 1269-1275
5. Mouridsen H.T., Bastholt L., Somers R., et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23 (1987) 1477-1483
6. Nielsen O.S., Dombernowsky P., Mouridsen H., et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78 (1998) 1634-1639
7. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13 (1995) 1537-1545
8. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 (1995) 610-630
9. Maurer H.M., Beltangady M., Gehan E.A., et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61 (1988) 209-220
10. Maurer H.M., Gehan E.A., Beltangady M., et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71 (1993) 1904-1922
11. McDowell H, Foot A, Bergeron C, et al. Metastatic rhabdomyosarcoma report: SIOP trial MMT98. In: 37th Annual Conference of the International Society of Paediatric Oncology SIOP 2005 - Vancouver, Canada, 21-24 Septembre 2005; p. O.110.11.
12. Koscielniak E., Rodary C., Flamant F., et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 20 (1992) 209-214
13. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 38 (1982) 143-151
14. Pappo A.S., Lyden E., Breneman J., et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol 19 (2001) 213-219
15. Carli M., Colombatti R., Oberlin O., et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22 (2004) 4787-4794
16. Sandler E., Lyden E., Ruymann F., et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 37 (2001) 442-448
17. Bisogno G., Ferrari A., Bergeron C., et al. The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 103 (2005) 1719-1724